Advertisements
Feeds:
Posts
Comments

Archive for the ‘LPBI Group, e-Scientific Media, DFP, R&D-M3DP, R&D-Drug Discovery, US Patents: SOPs and Team Management’ Category


Real Time Coverage of BIO 2019 International Convention, June 3-6, 2019 Philadelphia Convention Center, Philadelphia PA

Reporter: Stephen J. Williams, PhD @StephenJWillia2

Please follow LIVE on TWITTER using the following @ handles and # hashtags:

@Handles

@pharma_BI

@AVIVA1950

@BIOConvention

# Hashtags

#BIO2019 (official meeting hashtag)

Please check daily on this OPEN ACCESS JOURNAL for updates on one of the most important BIO Conferences of the year for meeting notes, posts, as well as occasional PODCASTS.

 

The BIO International Convention is the largest global event for the biotechnology industry and attracts the biggest names in biotech, offers key networking and partnering opportunities, and provides insights and inspiration on the major trends affecting the industry. The event features keynotes and sessions from key policymakers, scientists, CEOs, and celebrities.  The Convention also features the BIO Business Forum (One-on-One Partnering), hundreds of sessions covering biotech trends, policy issues and technological innovations, and the world’s largest biotechnology exhibition – the BIO Exhibition.

The BIO International Convention is hosted by the Biotechnology Innovation Organization (BIO). BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products.

 

Keynote Speakers INCLUDE:

Fireside Chat with Margaret (Peggy) Hamburg, MD, Foreign Secretary, National Academy of Medicine; Chairman of the Board, American Association for the Advancement of Science

Tuesday Keynote: Siddhartha Mukherjee (Author of the bestsellers Emperor of All Maladies: A Biography of Cancer and  The Gene: An Intimate History)

Fireside Chat with Jeffrey Solomon, Chief Executive Officer, COWEN

Fireside Chat with Christi Shaw, Senior Vice President and President, Lilly BIO-Medicines, Eli Lilly and Company

Wednesday Keynote: Jamie Dimon (Chairman JP Morgan Chase)

Fireside Chat with Kenneth C. Frazier, Chairman of the Board and Chief Executive Officer, Merck & Co., Inc.

Fireside Chat: Understanding the Voices of Patients: Unique Perspectives on Healthcare

Fireside Chat: FDA Town Hall

 

ALSO SUPERSESSIONS including:

Super Session: What’s Next: The Landscape of Innovation in 2019 and Beyond

Super Session: Falling in Love with Science: Championing Science for Everyone, Everywhere

Super Session: Digital Health in Practice: A Conversation with Ameet Nathawani, Chief Digital Officer, Chief Medical Falling in Love with Science: Championing Science for Everyone, Everywhere

Super Session: Realizing the Promise of Gene Therapies for Patients Around the World

Super Session: Biotech’s Contribution to Innovation: Current and Future Drivers of Success

Super Session: The Art & Science of R&D Innovation and Productivity

Super Session: Dealmaker’s Intentions: 2019 Market Outlook

Super Session: The State of the Vaccine Industry: Stimulating Sustainable Growth

 

See here for full AGENDA

Link for Registration: https://convention.bio.org/register/

The BIO International Convention is literally where hundreds of deals and partnerships have been made over the years.

 

BIO performs many services for members, but none of them are more visible than the BIO International Convention. The BIO International Convention helps BIO fulfill its mission to help grow the global biotech industry. Profits from the BIO International Convention are returned to the biotechnology industry by supporting BIO programs and initiatives. BIO works throughout the year to create a policy environment that enables the industry to continue to fulfill its vision of bettering the world through biotechnology innovation.

The key benefits of attending the BIO International Convention are access to global biotech and pharma leaders via BIO One-on-One Partnering, exposure to industry though-leaders with over 1,500 education sessions at your fingertips, and unparalleled networking opportunities with 16,000+ attendees from 74 countries.

In addition, we produce BIOtechNOW, an online blog chronicling ‘innovations transforming our world’ and the BIO Newsletter, the organization’s bi-weekly email newsletter. Subscribe to the BIO Newsletter.

 

Membership with the Biotechnology Innovation Organization (BIO)

BIO has a diverse membership that is comprised of  companies from all facets of biotechnology. Corporate R&D members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. The majority of our members are small companies – 90 percent have annual revenues of $25 million or less, reflecting the broader biotechnology industry. Learn more about how you can save with BIO Membership.

BIO also represents academic centers, state and regional biotech associations and service providers to the industry, including financial and consulting firms.

  • 66% R&D-Intensive Companies *Of those: 89% have annual revenues under $25 million,  4% have annual revenues between $25 million and $1 billion, 7% have annual revenues over $1 billion.
  • 16% Nonprofit/Academic
  • 11% Service Providers
  • 7% State/International Affiliate Organizations

Other posts on LIVE CONFERENCE COVERAGE using Social Media on this OPEN ACCESS JOURNAL and OTHER Conferences Covered please see the following link at https://pharmaceuticalintelligence.com/press-coverage/

 

Notable Conferences Covered THIS YEAR INCLUDE: (see full list from 2013 at this link)

  • Koch Institute 2019 Immune Engineering Symposium, January 28-29, 2019, Kresge Auditorium, MIT

https://calendar.mit.edu/event/immune_engineering_symposium_2019#.XBrIDc9Kgcg

http://kochinstituteevents.cvent.com/events/koch-institute-2019-immune-engineering-symposium/event-summary-8d2098bb601a4654991060d59e92d7fe.aspx?dvce=1

 

  • 2019 MassBio’s Annual Meeting, State of Possible Conference ​, March 27 – 28, 2019, Royal Sonesta, Cambridge

http://files.massbio.org/file/MassBio-State-Of-Possible-Conference-Agenda-Feb-22-2019.pdf

 

  • World Medical Innovation Forum, Partners Innovations, ARTIFICIAL INTELLIGENCE | APRIL 8–10, 2019 | Westin, BOSTON

https://worldmedicalinnovation.org/agenda-list/

https://worldmedicalinnovation.org/

 

  • 18th Annual 2019 BioIT, Conference & Expo, April 16-18, 2019, Boston, Seaport World Trade Center, Track 5 Next-Gen Sequencing Informatics – Advances in Large-Scale Computing

http://www.giiconference.com/chi653337/

https://pharmaceuticalintelligence.com/2019/04/22/18th-annual-2019-bioit-conference-expo-april-16-18-2019-boston-seaport-world-trade-center-track-5-next-gen-sequencing-informatics-advances-in-large-scale-computing/

 

  • Translating Genetics into Medicine, April 25, 2019, 8:30 AM – 6:00 PM, The New York Academy of Sciences, 7 World Trade Center, 250 Greenwich St Fl 40, New York

https://pharmaceuticalintelligence.com/2019/04/25/translating-genetics-into-medicine-april-25-2019-830-am-600-pm-the-new-york-academy-of-sciences-7-world-trade-center-250-greenwich-st-fl-40-new-york/

 

  • 13th Annual US-India BioPharma & Healthcare Summit, May 9, 2019, Marriott, Cambridge

https://pharmaceuticalintelligence.com/2019/04/30/13th-annual-biopharma-healthcare-summit-thursday-may-9-2019/

 

  • 2019 Petrie-Flom Center Annual Conference: Consuming Genetics: Ethical and Legal Considerations of New Technologies, May 17, 2019, Harvard Law School

http://petrieflom.law.harvard.edu/events/details/2019-petrie-flom-center-annual-conference

https://pharmaceuticalintelligence.com/2019/01/11/2019-petrie-flom-center-annual-conference-consuming-genetics-ethical-and-legal-considerations-of-new-technologies/

 

  • 2019 Koch Institute Symposium – Machine Learning and Cancer, June 14, 2019, 8:00 AM-5:00 PM  ET MIT Kresge Auditorium, 48 Massachusetts Ave, Cambridge, MA

https://pharmaceuticalintelligence.com/2019/03/12/2019-koch-institute-symposium-machine-learning-and-cancer-june-14-2019-800-am-500-pmet-mit-kresge-auditorium-48-massachusetts-ave-cambridge-ma/

 

Advertisements

Read Full Post »


Tweets and Retweets by @AVIVA1950 and by @pharma_BI for @USAIC and #USAIC2019 at the 13th Annual BioPharma & Healthcare Summit, Thursday, May 9, 2019, Marriott Hotel, Cambridge, MA

 

  1.  liked Tweets you were included in

    18 hours ago

    4 other likes

  2.  liked your Tweets

    18 hours ago

    10 other likes

 

  1.   Retweeted

    Alise Reicin discusses endpoints needed in and effect of cost of in Panel Discussion morning Networking break

  2.   Retweeted

    Alise Reicin Panel Discussion: best done as Basket&Umbrella trial; response rate 30-50% but Phase3 negative

    Translate Tweet

  3.   Retweeted

    Dr. William Chin design challenges with newer in recruiting patients; use Basket&Umbrella Trial design Live

 Retweeted

On risk | benefit: Long term impacts of treatment may be present for the life of the patient

  1.   Retweeted

    Discussion of cyber security at panel moderated by – realization that everything is interconnected: risks to business-critical functions. Much to learn from FinTech & others’ prior experience.

  2.   Retweeted

    Unexpected best thing about – at least three Zimbabweans in the crowd / on the stage.

  3.   Retweeted

    segueing into a discussion of safety, and risk tolerance. Prevention has a higher safety bar than treatment later in the disease process.

  4.   Retweeted

    Most humbling & touching moment: meeting an exec who nodded & teared up as I told him what we do His 9 yo child needs frequent contrast enhanced MRI scans for a rare disease. We felt like the smallest co at yet so important for hope & health

  5.  
  6.   Retweeted

    Great initiatives to bring CAR-T to India an automation to drug manufacturion

    Amazing moderator asking provoking question of best panel in responses by experts made known were different for competing rivals the aim is same best faster largest at lowest keeping maximized

  7.   Retweeted

    Dr. Bruce Chabner Talk: Old Phase 1,2,3 design not needed for & era based . very accommodating in Phase 1 trial design.

  8.   Retweeted

    Dr. Bruce Chabner panel discussion: selection based on new design paradigm; 40 drugs approved by accelerated approval for

  9.   Retweeted

    Dr. Mace Rothenberg talks for approvals vary greatly over multiple countries makes issues of ong-term design and post approval reimbursement

  10.   Retweeted

    Talk : design now depends on systems e.g. organelle delivery. only wants accelerated approval not conditional approval. Surrogate markers critical for new trial design

  11.   Retweeted

    Dr. Rob Scott Panel Talk crisis in not in . Lowest investment in development. Physicians using SAME design for . use in trails increasing

  12.   Retweeted

    Dr. Rob Scott on design @usaic2019: Regulators as partners not barriers but burden of efficacy on . Can use advertising to increase recruitment as 70% willing participants live too far away so use &

  13.   Retweeted

    Dr. Rob Scott discusses recruitment and burdens : prefers to do in house & not use CRO as CRO less effective in monitoring trial

  14.   Retweeted

    “Some drug platforms are mature enough to fall under the practice of medicine” – Tim Yu of

  15.   Retweeted

    Closing R&D strategies panel at is with NIBR’s Janssen’s and Takeda’s Andy Plump. Moderator Martin Mackay (now of newco Rallybio) asks: What are you most excited about?

  16.   Retweeted

    Talk of indexed pricing model in the US may be a challenge for access to other parts of the world, says a speaker on rare disease panel

  17.   Retweeted

    The biggest problem that we have in the industry is the lack of empathy, says Chris Viehbacher

  18.   Retweeted

    Tim Yu’s example left a room full of seasoned biopharma R&D execs wowed. More background here:

  19.   Retweeted

    (May 9, Boston) will feature plenary panel on Emerging R&D Strategies moderated by Dr. Martin Mackay, Co-Founder, Rallybio, with of , Andy Plump of , of Janssen, Michael Ehler of -> register today

  20.   Retweeted

    Check out my latest article: Where is Oncology Drug Development Heading Next? Hear From Top KOLs at 13th BioPharma Summit May 9, Boston via

  21.   Retweeted

    Check out my latest article: One in a Million: Emerging Trends in Rare Diseases at 13th annual BioPharma Summit- May 9, Boston via

  22.   Retweeted

    Check out my latest article: Chris Viehbacher, Gurnet Point Capital joins the USAIC Advisory Board. Please join Chris & other leaders at our annual BioPharma Summit, May 9, Boston via

  23.   Retweeted

    Check out my latest article: R&D Panel: BioPharma KOLs Debate R&D Strategies & Trends at 13th annual BioPharma Summit, May 9, Boston via

  24.   Retweeted

    Check out my latest article: What Does The Future Hold For Drug Development & Clinical Trials? Hear Predictions From Top Drug Developers at the 13th BioPharma Summit May Boston 9 via

  25.   Retweeted
  26.   Retweeted

    Value and Access – The Ongoing Debate.The BioPharma Summit will feature this special session. Join the discussion with BioPharma KOLs via

  27.   Retweeted

    BioPharma Manufacturing in the Future: Hear KOLs Debate the Challenges and Opportunities at the 13th annual BioPharma Summit, May 9, Boston via

  28.   Retweeted

    Our 13th Biopharma & Healthcare Summit has kicked off with introductory remarks from USAIC President Karun Rishi and emcee Dr. Andrew Plump, President of R&D for Takeda.

  29.   Retweeted

    The session is starting as I attend the focused on US-India bio-pharma healthcare summit. The focus is on and to deliver compelling affordable care with key role for technologies.

  30.   Retweeted

    Carl June believes we’re only a few years away from outpatient CAR therapies, with no need for intensive infrastructure with ICU.

  31.   Retweeted

    Dr. Maus ⁩ monitoring data from clinical trial is very important development of new targets multiple drugs multiple mechanism multiple specificities more modification to one cell contamination results

  32.   Retweeted

    “Cancer is a collection of rare diseases” – , Director of Clinical Research, Cancer

  33.   Retweeted

    Sanat Chattopadhyay of US Merck says costs of manufacturing in US/Europe is significantly higher because technology deployed is ancient, both in small molecules and biologics.

  34.   Retweeted

    Rare disease taking center stage as technologies mature, panel moderated by CRISPR Therapeutics CEO Samarth Kulkarni

  35.   Retweeted
    Replying to  

    Enjoyed moderating the panel on manufacturing in the future as bio pharma companies explore ways to deliver drugs at affordable price and address access challenges. Digital innovation in manufacturing and supply chains will be key.

  36.   Retweeted

    Price is part of doing business…if you are not able to define value, you are sunk, says Chris Viehbacher Gurnet Point Capital

  37.   Retweeted

    All diseases are unique Your perspective changes when you or someone you love is diagnosed with a life-altering disease – rare diseases panel

  38.   Retweeted

    Arun Singhal, addl secretary, health ministry speaks about Ayushman Bharat, trade margin rationalisation, clinical trial rules at meeting

  39.   Retweeted

    Clinical trials in India picking up steadily, says Eswara Reddy, DCGI

  40.   Retweeted

    Regulators will “provide complete support” for clinical trials in India provided drug developers meet the new requirements – Drug Controller General of India Eswara Reddy

  41.   Retweeted

    discusses prevention and treatment of early disease e.g. precancer The challenge is to work out the commercial model says organize around prevention Early diagnosis / discovery of disease processes saves lives (’s raison d’etre)

  42. AMAZING EVENT @AVIVA11950 13th Annual & Healthcare Summit, Thursday, May 9, 2019, Marriott Hotel, Cambridge, MA via

  43. Dr. James Bradner, President, Novartis Institutes for BioMedical Research biophysical biochemical protein degradation – rewire disease cells with biomolecules combing propertitie of permiability of small molecules

  44. World PGD Growth of 4% in India 31%

  45.   Retweeted

    Takeda R&D Head Andy Plump asks question from audience to peers on stage: “I’ve been in the industry for 18 years and I can’t understand why a clinical trial costs so much. Why does it?”

  46.   Retweeted

    Manufacturing in the age of individualized medicine? We may need a completely different thinking for that says Paul Mckenzie, Biogen

  47.   Retweeted

    The so-called low-cost manufacturing edge of India will go away in a few years, says Hari Bhartia, Jubilant…being closer to the customer will be important

  48.   Retweeted

    Tricky question: getting patients to cancer centers to participate in clinical trials. Should patients be reimbursed for long travels and other expenses or will it be seen as an inducement?

  49.   Retweeted

    A chance to collaborate with my old colleague & friend ! -> another point from same panel: AbbVie CMO Rob Scott predicts tele-health solutions for clinical trial patients will be scalable soon

  50.   Retweeted

    Carl June: There are no CAR-T clinical trials in India. But says countries like India could eventually leapfrog to next gen (outpatient) cell therapy which will require less infrastructure + lower COG

  51.   Retweeted

    The 13th Annual BioPharma & Healthcare Summit is being kicked off by Andrew Plump. In his opening remarks, he commented that we should feel privileged as attendees because not even or is invited to this meeting.

  52.   Retweeted

    A well-represented panel of scientists, CEOs and entrepreneurs discuss a range of discovery research from CAR-Ts to small molecules…on the same panel is Arjun Surya of Curadev that licensed a preclinical oncology lead to Takeda.

  53. The promise of India is the largest democracy, the educated workforce the size of the market for therapeutics, access and price, reimbursement and regulation. DCGI the analogue of FDA is very active and innovated the challenge of 1.3 Billion a population of patients

  54. Great Leader in immunotherapy, Carl June early inventor and endless commitment to patient a Pro for BioPharma

  55. GREAT Conference of who is who in BioPharma, Boston at the top 500 startats of Biotech in Cambridge, MA ten years afo only a handful, boost by Novartis HQS in Cambridge, MA

  56. Liked the analogy of

Read Full Post »


Tweets by @pharma_BI and @AVIVA1950 at #GenMed2019 on Translating Genetics into Medicine, April 25, 2019, 8:30 AM – 6:00 PM, The New York Academy of Sciences, 7 World Trade Center, 250 Greenwich St Fl 40, New York

  1. ⁩ CC-220 binds to proteins degraded exposure correlates with B cell depletion normal T cells SLE IS THE NEW INDICATION of a repurpose of thalidomide and another drug for melanoma GENETIC DOSE-response portal: genetics, interrogation pleiotropy data analysis visual

  2. Dr. Pledge ⁦ human genetics and drug discovery drug R&D attrition drug value to patient in decline failure in Phase 2&3 lack of efficacy cause hi drug price human as the model organism longitudinal test therapeutics on human phyno

  3. from genetics to target selection finding genetic evidence new opportunities cross-biobank research other RWD genetic data enabler: biobanks FINGEN (Finland collaboration) 23andme GWAS case control prevention disease trajectories

  4. Dr. Rader UPenn Gain of function mutation increase HDL-C therapeutic relevance LCAT Fig below is on TRL

  5. Dr. Rader UPenn Abeta- lipoproteinemia reduce LDL in serum-secretion increase lipid in liver Lomitspide Mipomersen rare Mendelian disorders yielded targets common diseases triglyceride-rich Lipoff protein TG LIPASE critical regulator of ApoC-III ANGPTL3 ANGPTL4 human knockouts

  6. CRISPR tool to perturb enhancers REGULATORY elements by oligo pool pool of gRNA ScanDel pooled deletion screen HPRT1 Utica acid metabolism &CNS function scan deletions across the HPRT1 locus long deletion between two CRISPR cuts one deletion

  7. Dr. Gupta ⁦⁩ ⁦⁩ 6p24 SNP coronary disease Justine acetylation vascular tissue variant in stem-cells differentiation into vascular endothelial cells or vascular muscle cells CRISPR/Cas9 heterozygous deletion

    Translate Tweet

  8. In autism genes identified interplay of congenital heart disease babies to develop therapeutics for autism genetics but Genomics not applicable for an anatomical dysfunction

  9. chromatin modifiers in De novo mutation related to CVD

  10. APA – aldesteron somatic mutations in K+ channel KCNJ5 – instead of only K it conducts K+ and NC- that mutant activation

  11. Adrenal gland behave like tumor antibiotics as therapeutic to rare mutation K NaCl in Kidney

  12. Undiagnozed Dx – rare mutation on gene NLRC4 a core inflasome protein IL-1beta and IL-18 New autoinflammatory Dx to de novo mutation Total novel disease genes HTN renal salt reabsorption and K+ secretions – mutations phosphorelated KLHL3-s433

  13. @AVIVA2950 Common variants small effect on polygenic risk score purifying selection heterozygous mutation dominant lethals caused by mutations Sequence outside coding regions utility coding than non-coding variants SEQ EXOME 20,000 genes 1% genome SLC26A3

  14. Prof. Lifting, Rockefeller University alleles genotype and phenotype links HTN cause death single mutation how kidney handle salt: extreme BP modulate loci to normalize BP Strategy to lower salt to control BP FDA identify genes vs biological

  15. Immune Infiltration Hashimoto Crohn’s RNA-Seq 73 infiltration phenotypes amount of cell types tissue-specific genetics CUX1 gene expression neutrophils in Lungs

  16. Immune-diseases GWAS Variants Treg role in homeostasis on immune system affect 10% of European Population RA, biological vs small molecules risk allele gene expression

  17. Population with high risks for BRCA1 or 2 1 in 30 Rick in African American carriers BRCA1or2 60% no cancer occurs ⁦

  18. Allele-specific reporter assays C G luciferase Multiple regulatory risk allele CRISPR/Cas9 genome editing allele vs Epigene Editing point mutation synthetic transcription factor covalent histone enhancer activation via dCas9-P300 10-6 kB away

  19. Hyperglycemia during pregnancy adverse pregnancies outcome genetic variation on Chromosome 10 1st intron of HKDC1 epigenetic signals of gene regulation

  20. GWAS vs gene regulation non coding regions variant perturbed gene expression target gene identification difficult <50 % enhancers target their nearest gene linkage disequilibrium sensitivity of system perturbation of gene casual gene function Epi

  21. Full picture , longitudinal vs cross section interventions, genetics to predict obesity by Test vs Disease susceptibility of newborn babies top 5% vs 20% for clinical sensitivity specificity 0.8 history BETTER predictor S/S 0.5

  22. today is DNA Day, Humsn Grnome completed, both 4/25 link between and Genomics in way Broder a scope

Read Full Post »


42.5K impressions over this 28 day period, 1.7K impressions per day, March 17, 2019 – April 11, 2019

 

Your Tweets earned 42.5K impressions over this 28 day period

2.0K4.0K6.0K8.0K50 Mar 17Mar 24Mar 31Apr 7
YOUR TWEETS
During this 28 day period, you earned 1.7K impressions per day.
Engagements
Showing 28 days with daily frequency
Engagement rate
1.9%
Apr 11
0.3% engagement rate
Link clicks
19
Apr 11
1 link click
On average, you earned 1 link clicks per day
Retweets
95
Apr 11
5 Retweets
On average, you earned 3 Retweets per day
Likes
173
Apr 11
5 likes
On average, you earned 6 likes per day
Replies
0
Apr 11
0 replies
On average, you earned 0 replies per day
SOURCE

Read Full Post »


The #WMIF19 Influencers via ‘s  Hashtags http://bit.ly/WMIF19 – By Mentions and By Tweets Ranked #4: @pharma_BI and #2: @AVIVA1950, respectively. Ranked #3 via NodeXL Betweenness Centrality http://bit.ly/2KB6cPN

 

Ranked #3 via NodeXL Betweenness Centrality http://bit.ly/2KB6cPN

@phsinnovation
@evankirstel
@aviva1950

New Rankings

#4 on Mentions: @pharma_BI and

#2 on number of Tweets: @AVIVA1950

via

‘s  Hashtags http://bit.ly/WMIF19

 

 

Third Place in Top 10 Influencers 

Ranked #3 via NodeXL Betweenness Centrality http://bit.ly/2KB6cPN

@phsinnovation
@evankirstel

 Tweets, N=152

 

SOURCE

https://nodexlgraphgallery.org/Pages/Graph.aspx?graphID=193125

 

 

line separator end

 

 

03/10 –

03/16

03/17 –

03/23

03/24 –

03/30

03/31 –

04/06

04/07 –

04/13

Likes

9

4

29

27

123

Followers

358

360

363

383

391

Friends

1.4K

1.4K

1.5K

1.5K

1.5K

Mention Reach

1.7K

395

1.4K

33.6K

23.7K

Mentions

10

3

16

3

14

Replies

0

0

0

0

0

Retweet Reach

6.4K

784

2.1K

73.6K

129.9K

Retweets

7

2

12

20

66

Tweets

12

8

56

44

154

 

 

 

AVIVA1950

Twitter

 

 

 

 

 

04/07 – 04/13

Δ 7d

Last 5w

 

Likes

123

+96

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Followers

391

+8

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Friends

1.5K

+7

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Mention Reach

23.7K

-9.9K

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Mentions

14

+11

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Replies

0

+0

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Retweet Reach

129.9K

+56.3K

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Retweets

66

+46

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Tweets

154

+110

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SOURCE

From: SumAll <sumall@sumall.com>

Date: Sunday, April 14, 2019 at 5:05 PM

To: “<Aviva Lev-Ari>”, <PhD>, Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: My Weekly Digest: Week of Apr 7, 2019

 

Top 3 Ranked by Betweenness Centrality in Top 10 Influencers   Twitter Analytics by NodeXL for #WMIF19 by @PHSInnovation  at World Medical Innovation Forum ARTIFICIAL INTELLIGENCE, Boston, MA USA, Monday, April 8-10, 2019

https://pharmaceuticalintelligence.com/2019/04/11/top-3-ranked-by-betweenness-centrality-in-top-10-influencers-wmif19-phsinnovation-evankirstel-aviva1950-tweeter-analytics-by-nodexl-http-bit-ly-2kb6cpn-for-wmif19-by-phs/

 

Tweets, ReTweets and Likes by @AVIVA1950 and by @pharma_BIusing @PHSInnovation and #WMIF19 during Day One, Two and Three of World Medical Innovation Forum ARTIFICIAL INTELLIGENCE, Boston, MA USA, Monday, April 8-10, 2019

https://pharmaceuticalintelligence.com/2019/04/11/tweets-retweets-and-likes-by-aviva1950-and-by-pharma_bi-using-phsinnovation-and-wmif19-during-day-one-two-and-three-of-world-medical-innovation-forum-artificial-intelligence-boston-ma-us/

 

LIVE Day One – World Medical Innovation Forum ARTIFICIAL INTELLIGENCE, Westin Copley Place, Boston, MA USA, Monday, April 8, 2019

https://pharmaceuticalintelligence.com/2019/04/08/live-day-one-world-medical-innovation-forum-artificial-intelligence-westin-copley-place-boston-ma-usa-monday-april-8-2019/

 

LIVE Day Two – World Medical Innovation Forum ARTIFICIAL INTELLIGENCE, Boston, MA USA, Monday, April 9, 2019

https://pharmaceuticalintelligence.com/2019/04/09/live-day-two-world-medical-innovation-forum-artificial-intelligence-boston-ma-usa-monday-april-9-2019/

 

LIVE Day Three – World Medical Innovation Forum ARTIFICIAL INTELLIGENCE, Boston, MA USA, Monday, April 10, 2019

https://pharmaceuticalintelligence.com/2019/04/10/live-day-three-world-medical-innovation-forum-artificial-intelligence-boston-ma-usa-monday-april-10-2019/

 

 

Read Full Post »


Top 3 Ranked by Betweenness Centrality in Top 10 Influencers   Twitter Analytics by NodeXL for #WMIF19 by @PHSInnovation  at World Medical Innovation Forum ARTIFICIAL INTELLIGENCE, Boston, MA USA, Monday, April 8-10, 2019

 

www.worldmedicalinnovation.org

 

‘s Hashtags  – Twitter Analytics published for http://bit.ly/WMIF19 

  • [Top 10 by Mentions – @pharma_BI = 4 with 181 mentions]  
  • [Top 10 by Tweets @AVIVA1950 = 2 with 229 Tweets (N = 152 Direct messages)]
 Pinned Tweet

⚡️As World Forum comes to a close, here are TOP via ‘s Hashtags 🙏 to organizers for a stellar event & to all on for a robust conversation! 👏

 

Third Place in Top 10 Influencers 

  

 Tweets, N=152

 

SOURCE

https://nodexlgraphgallery.org/Pages/Graph.aspx?graphID=193125

 

#WMIF19_2019-04-09_09-37-27.xlsx

View an interactive version of this graph (experimental)

From:

Connected Action NodeXL-Reports

Uploaded on:

April 09, 2019

Short Description:

 

#WMIF19 via NodeXL http://bit.ly/2KB6cPN

@phsinnovation
@evankirstel
@aviva1950
@partnersnews
@beyondverbal
@dme_jun
@seemacms
@bwhihub
@massgovernor
@doylet

Top hashtags:
#wmif19
#ai
#healthcare
#artificialintelligence
#boston
#innovation
#wmif
#aiinpharma

Description:

 

Description

The graph represents a network of 731 Twitter users whose recent tweets contained “#WMIF19”, or who were replied to or mentioned in those tweets, taken from a data set limited to a maximum of 18,000 tweets. The network was obtained from Twitter on Tuesday, 09 April 2019 at 16:40 UTC.

The tweets in the network were tweeted over the 9-day, 18-hour, 32-minute period from Saturday, 30 March 2019 at 22:04 UTC to Tuesday, 09 April 2019 at 16:37 UTC.

Additional tweets that were mentioned in this data set were also collected from prior time periods. These tweets may expand the complete time period of the data.

There is an edge for each “replies-to” relationship in a tweet, an edge for each “mentions” relationship in a tweet, and a self-loop edge for each tweet that is not a “replies-to” or “mentions”.

The graph is directed.

The graph’s vertices were grouped by cluster using the Clauset-Newman-Moore cluster algorithm.

The graph was laid out using the Harel-Koren Fast Multiscale layout algorithm.

 

Highlighted in RED rankings for

@AVIVA1950

@pharma_BI

http://pharmaceuticalintelligence.com 

 

Top Influencers: Top 10 Vertices, Ranked by Betweenness Centrality

 

@phsinnovation
Smart Tweet

 

@evankirstel
Smart Tweet

 

@aviva1950
Smart Tweet

 

@partnersnews
Smart Tweet

 

@beyondverbal
Smart Tweet

 

@dme_jun
Smart Tweet

 

@seemacms
Smart Tweet

 

@bwhihub
Smart Tweet

 

@massgovernor
Smart Tweet

 

@doylet

 

Top URLs in Tweet in G3:

 

[3] https://www.fitzroyhealth.com/wmif
[2] https://worldmedicalinnovation.org/agenda/

[2] https://twitter.com/aviva1950/status/1115292614402695169 

[1] https://www.fda.gov/downloads/MedicalDevices/DigitalHealth/SoftwareasaMedicalDevice/UCM635052.pdf
[1] https://www.youtube.com/watch?v=AGhC864Wh-0

[1] https://www.youtube.com/watch?v=_wIO2EAM1xw

[1] https://twitter.com/happysylvie/status/1115639128455041025
[1] https://twitter.com/BayerUS/status/1114211171517784064
[1] https://twitter.com/BayerUS/status/1115245439173967872
[1] https://twitter.com/BayerPharma/status/1115259254003458049

 

Top Domains in Tweet in G2:

 

[26] twitter.com
[10] bwhclinicalandresearchnews.org
[6] worldmedicalinnovation.org
[5] linkedin.com
[2] lnkd.in
[1] connectwithpartners.org
[1] healthdatamanagement.com
[1] pharmaceuticalintelligence.com 
[1] youtube.com
[1] npr.org

 

Top Words in Tweet in G2:

 

[415] #wmif19
[236] phsinnovation
[163] #ai
[124] ai
[93] data
[91] dr
[82] care
[81] aviva1950 
[80] pharma_bi 
[78] healthcare

 

Top Mentioned in Entire Graph:

 

@phsinnovation
Follow Smart Tweet

 

@partnersnews
Follow Smart Tweet

 

@aviva1950
Follow Smart Tweet

 

@seemacms
Follow Smart Tweet

 

@pharma_bi
Follow Smart Tweet

 

@nvidia
Follow Smart Tweet

 

@brighamwomens
Follow Smart Tweet

 

@gehealthcare
Follow Smart Tweet

 

@massgovernor
Follow Smart Tweet

 

@evankirstel
Follow Smart Tweet

 

 

 

Top Mentioned in G1:

 

@phsinnovation
Follow Smart Tweet

 

@partnersnews
Follow Smart Tweet

 

@gehealthcare
Follow Smart Tweet

 

@nvidia
Follow Smart Tweet

 

@aviva1950
Follow Smart Tweet

 

@seemacms
Follow Smart Tweet

 

@kieranmurphyceo
Follow Smart Tweet

 

@constancelehman
Follow Smart Tweet

 

@terribresenham
Follow Smart Tweet

 

@bayer
Follow Smart Tweet

 

Top Mentioned in G2:

 

@phsinnovation
Follow Smart Tweet

 

@aviva1950
Follow Smart Tweet

 

@brighamwomens
Follow Smart Tweet

 

@partnersnews
Follow Smart Tweet

 

@pharma_bi
Follow Smart Tweet

 

@massgovernor
Follow Smart Tweet

 

@massgeneralnews
Follow Smart Tweet

 

@bwhihub
Follow Smart Tweet

 

@chencao
Follow Smart Tweet

 

Top Mentioned in G5:

 

@evankirstel
Follow Smart Tweet

 

@phsinnovation
Follow Smart Tweet

 

@irmaraste
Follow Smart Tweet

 

@evirahealth
Follow Smart Tweet

 

@philips
Follow Smart Tweet

 

@aviva1950
Follow Smart Tweet

 

@pharma_bi
Follow Smart Tweet

 

@health_xl
Follow Smart Tweet

 

@nvidia
Follow Smart Tweet

 

@edvaldez8888
Follow Smart Tweet

 

 

Top Domains in Tweet in G2:

 

[26] twitter.com
[10] bwhclinicalandresearchnews.org
[6] worldmedicalinnovation.org
[5] linkedin.com
[2] lnkd.in
[1] connectwithpartners.org
[1] healthdatamanagement.com
[1] pharmaceuticalintelligence.com 
[1] youtube.com
[1] npr.org

 

Top Words in Tweet in G2:

[415] #wmif19
[236] phsinnovation
[163] #ai
[124] ai
[93] data
[91] dr
[82] care
[81] aviva1950 
[80] pharma_bi 
[78] healthcare

 

Top Word Pairs in Tweet in Entire Graph:

 

[131] phsinnovation,#wmif19
[129] medical,innovation
[105] world,medical
[102] pharma_bi,aviva1950 
[101] innovation,forum
[59] #wmif19,phsinnovation
[55] looking,forward
[52] first,look
[51] jensen,huang
[47] #wmif19,evankristel

 

Top Word Pairs in Tweet in G1:

 

[36] phsinnovation,#wmif19
[23] innovation,forum
[22] world,medical
[22] medical,innovation
[20] #wmif19,phsinnovation
[20] nvidia,ceo
[19] jensen,huang
[18] pharma_bi,aviva1950 
[18] #wmif,#wmif19
[17] looking,forward

 

Top Word Pairs in Tweet in G2:

 

[77] pharma_bi,aviva1950 
[72] phsinnovation,#wmif19
[50] medical,innovation
[38] #wmif19,evankristel
[38] evankristel,pharma_bi 
[31] first,look
[30] today,s
[25] world,medical
[25] innovation,forum
[24] aviva1950,phsinnovation 

 

 

Top Replied-To in Entire Graph:

 

@phsinnovation
Follow Smart Tweet

 

@pharma_bi
Follow Smart Tweet

 

@constancelehman
Follow Smart Tweet

 

@massgovernor
Follow Smart Tweet

 

@seemacms
Follow Smart Tweet

 

Top Replied-To in G2:

 

@phsinnovation
Follow Smart Tweet

 

@pharma_bi
Follow Smart Tweet

 

@massgovernor
Follow Smart Tweet

 

@brighamwomens
Follow Smart Tweet

 

@masseyeandear
Follow Smart Tweet
@landmaad
Follow Smart Tweet

 

@peterrchai
Follow Smart Tweet

 

@gilpress
Follow Smart Tweet

 

@nancyatheart
Follow Smart Tweet

 

@brighamresearch
Follow Smart Tweet

 

Download the Graph Data as a NodeXL Workbook

Download the Graph Data as GraphML

Download the NodeXL Options Used to Create the Graph

 

Read Full Post »


Tips on 280 Character Tweets on Twitter.com

 

The FIT members @LPBI Group are edified by the following advice and tips on TWEETING

 

From: Gail Thornton <gailsthornton@yahoo.com>

Reply-To: Gail Thornton <gailsthornton@yahoo.com>

Date: Saturday, March 2, 2019 at 5:33 PM

To: Rick Mandahl <rmandahl@gmail.com>, Amnon Danzig <amnon.danzig@gmail.com>, Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: Re: In 280 Characters

Aviva:

Please let me offer some recommendations, suggestions and advice on how to compose tweets moving forward. These tips are a departure for how you currently compose and post tweets.

You need to find businesses, universities, research centers, who have a large number of followers (upwards of 500,000) and target them with your tweets.

Keep Tweets conversational.   Avoid business jargon when possible.

Think about how your content will be consumed by your followers. Would they want to retweet it or pass it along to others? Incorporate humor, inspiration and newsworthy content to draw followers in.

Twitter is particularly powerful at driving “amplification” for brand messages–retweets that share your message. In fact, 78% of user engagement with a brand’s Tweets is in the form of Retweets, This is essential in getting more people to read your tweets.

Tweets that contained more adverbs and verbs have a higher click-through rate than tweets with more nouns and adjectives. So the general rule that action words make for stronger, more compelling writing is also true for Tweets.

SUPER IMPORTANT: 

Consider creating a hashtag that is short, recognizable by followers, and allows them to easily follow along. If you’re using an existing hashtag, ensure you’re adding value to the conversation. The volume of hashtags is important as well: one or two hashtags can get you up to two times more engagement than tweets without hashtags (not 8-9-10), according to a study by Buddy Media/Salesforce.

There is usually a spike in retweets among those in the 71-100 character range—the “medium” length tweets column in this chart.   

 

Tweets with images received 18% more click-throughs, 89% more favorites, and 150% more retweets.

There is a 30% greater engagement rate when Tweets are published during the day (between 8AM-7PM). This makes sense if you consider the majority of news, store hours and activities happen during the day.

For example, a content calendar that you should adapt for LPBI. All businesses with Twitter accounts have a monthly content calendar that precisely and strategically lays out each day what you want to tweet. It is not a random act of tweeting that gets you noticed.

  • On Monday, you could launch a Twitter-only promotion for your followers. Tweet an online offer code or a secret word for customers to use when they visit your business.
  • On Tuesday, tweet a behind-the-scenes tour of your business. Highlight how your products are made or where they are sourced from.
  • On Wednesday: Create a regular series of Tweets that are informative or surprising such as tips.
  • On Thursday, retweet a few positive customer reviews. Or tweet some industry-related news your followers might find interesting.
  • Finally on Fridays, give customers a glimpse into your workplace culture. Tweet photos or Vine videos of your colleagues and employees hard at work or having fun.

Read Full Post »

Older Posts »